[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1110783T1 - Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων - Google Patents

Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων

Info

Publication number
CY1110783T1
CY1110783T1 CY20101100789T CY101100789T CY1110783T1 CY 1110783 T1 CY1110783 T1 CY 1110783T1 CY 20101100789 T CY20101100789 T CY 20101100789T CY 101100789 T CY101100789 T CY 101100789T CY 1110783 T1 CY1110783 T1 CY 1110783T1
Authority
CY
Cyprus
Prior art keywords
growth factor
monoclonal antibodies
antibodies against
against growth
pharmaceutical composition
Prior art date
Application number
CY20101100789T
Other languages
English (en)
Inventor
Kyung Jin Kim
Yi-Chi Su
Original Assignee
Galaxy Biotech, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110783(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galaxy Biotech, Llc filed Critical Galaxy Biotech, Llc
Publication of CY1110783T1 publication Critical patent/CY1110783T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ένα εξουδετερωτικό μονοκλωνικό αντίσωμα κατά αυξητικού παράγοντα ηπατοκυττάρων, σε μια φαρμακευτική σύνθεση που περιέχει αυτό, και σε μεθόδους θεραπευτικής αγωγής περιλαμβάνουσες τη χορήγηση μιας τέτοιας φαρμακευτικής σύνθεσης σε έναν ασθενή, τέτοιας όπως για την αναστολή γλοιοβλαστώματος.
CY20101100789T 2004-04-15 2010-08-30 Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων CY1110783T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/825,060 US20040208876A1 (en) 2003-04-18 2004-04-15 Monoclonal antibodies to hepatocyte growth factor
EP04781281A EP1734995B1 (en) 2004-04-15 2004-08-13 Monoclonal antibodies to hepatocyte growth factor

Publications (1)

Publication Number Publication Date
CY1110783T1 true CY1110783T1 (el) 2015-06-10

Family

ID=35320045

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100789T CY1110783T1 (el) 2004-04-15 2010-08-30 Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων

Country Status (26)

Country Link
US (5) US20040208876A1 (el)
EP (2) EP2204191A1 (el)
JP (2) JP4594381B2 (el)
KR (1) KR101072736B1 (el)
CN (1) CN1964738A (el)
AT (1) ATE473760T1 (el)
AU (1) AU2004319276C1 (el)
BR (1) BRPI0418745A (el)
CA (1) CA2563080C (el)
CR (1) CR8698A (el)
CY (1) CY1110783T1 (el)
DE (1) DE602004028168D1 (el)
DK (1) DK1734995T3 (el)
ES (1) ES2346886T3 (el)
HK (1) HK1094167A1 (el)
HR (1) HRP20100521T1 (el)
IL (1) IL178474A (el)
MX (1) MXPA06011822A (el)
NO (1) NO20065227L (el)
NZ (1) NZ550324A (el)
PL (1) PL1734995T3 (el)
PT (1) PT1734995E (el)
RU (1) RU2361879C2 (el)
SI (1) SI1734995T1 (el)
WO (1) WO2005107800A1 (el)
ZA (1) ZA200609407B (el)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
MEP31408A (en) * 2003-07-18 2010-10-10 Abgenix Inc Specific binding agents to hepatocyte growth factor
US7476724B2 (en) * 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
EP1885400A4 (en) * 2005-06-02 2011-01-26 Galaxy Biotech Llc METHOD FOR THE TREATMENT OF BRAIN TUMORS BY ANTIBODIES
BRPI0617378B8 (pt) 2005-10-14 2022-09-20 Chugai Pharmaceutical Co Ltd Uso de um inibidor de il-6 para produzir uma composição farmacêutica para suprimir dano a um ilhota transplantada depois do transplante de ilhota; e aperfeiçoar a viabilidade de uma ilhota em um transplante de ilhota
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
KR20080084818A (ko) * 2005-11-25 2008-09-19 각고호우징 게이오기주크 전립선암 치료제
EP3135298B1 (en) 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
AR061171A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch)
EP2380908A1 (en) 2006-06-02 2011-10-26 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
WO2008090901A1 (ja) 2007-01-23 2008-07-31 Shinshu University 慢性拒絶反応抑制剤
MX2009013886A (es) * 2007-06-25 2010-01-27 Amgen Inc Composiciones de agentes de aglutinacion especifica al factor de crecimiento de los hepatocitos.
CL2009000843A1 (es) * 2008-04-11 2009-07-24 Galaxy Biotech Llc Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
MX2010012290A (es) * 2008-05-14 2011-02-21 Amgen Inc Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer.
JP5544290B2 (ja) 2008-06-05 2014-07-09 独立行政法人国立がん研究センター 神経浸潤抑制剤
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
CN101555912B (zh) * 2009-04-29 2012-10-03 深圳市特辰科技股份有限公司 一种转轮式自锁安全制动装置及其工作方法
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
JP2013537918A (ja) 2010-09-27 2013-10-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
KR20140045440A (ko) 2011-06-30 2014-04-16 제넨테크, 인크. 항-c-met 항체 제제
CZ303636B6 (cs) * 2011-08-19 2013-01-23 Invos, Spol. S R. O. Biokontejner pro sber bioodpadu a komunálního odpadu
CN103974720A (zh) 2011-09-09 2014-08-06 安姆根有限公司 C-met蛋白质用于预测抗肝细胞生长因子(“hgf”)抗体在食管癌和胃癌患者中的功效的用途
CA2843771A1 (en) 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
WO2014153117A2 (en) * 2013-03-14 2014-09-25 Alder Biopharmaceuticals, Inc. Antibodies to hgf and compositions containing
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
EP3698808A4 (en) 2017-10-20 2021-07-14 Hyogo College Of Medicine MEDICAL COMPOSITION CONTAINING ANTI-IL-6 RECEPTOR ANTIBODIES FOR THE PREVENTION OF POSTOPERATIVE ADHESION

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US722041A (en) * 1902-11-24 1903-03-03 Mail Belting Company Conveyer-belt.
JP2564486B2 (ja) 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
GB9003621D0 (en) 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DK0922102T3 (da) * 1996-07-03 2010-08-16 Genentech Inc Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
WO2000012560A1 (en) 1998-08-28 2000-03-09 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
US7459536B1 (en) 1999-11-09 2008-12-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HGF-SF monoclonal antibody combinations
AU2002355249A1 (en) 2001-07-26 2003-02-17 Eli Lilly And Company Interleukin-1 beta antibodies
AU2002357388A1 (en) 2001-12-27 2003-07-24 The United States Of America, As Represented By The Department Of Veterans Affairs Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
AU2003270118A1 (en) * 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
CA2528343A1 (en) 2003-06-06 2005-01-06 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
EP1648493B1 (en) 2003-07-07 2009-12-09 Van Andel Research Institute Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
MEP31408A (en) * 2003-07-18 2010-10-10 Abgenix Inc Specific binding agents to hepatocyte growth factor
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
EP1885400A4 (en) * 2005-06-02 2011-01-26 Galaxy Biotech Llc METHOD FOR THE TREATMENT OF BRAIN TUMORS BY ANTIBODIES
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
CA2563080A1 (en) 2005-11-17
IL178474A (en) 2011-04-28
CA2563080C (en) 2015-01-27
US7494650B2 (en) 2009-02-24
US20120064066A1 (en) 2012-03-15
MXPA06011822A (es) 2007-03-23
RU2006140257A (ru) 2008-05-20
RU2361879C2 (ru) 2009-07-20
EP2204191A1 (en) 2010-07-07
ZA200609407B (en) 2008-07-30
US20090104192A1 (en) 2009-04-23
US20040208876A1 (en) 2004-10-21
JP2007532643A (ja) 2007-11-15
KR101072736B1 (ko) 2011-10-11
WO2005107800A1 (en) 2005-11-17
DK1734995T3 (da) 2010-10-25
JP2011012067A (ja) 2011-01-20
US20070160613A1 (en) 2007-07-12
NO20065227L (no) 2007-01-10
HRP20100521T1 (hr) 2010-10-31
JP4594381B2 (ja) 2010-12-08
AU2004319276B2 (en) 2010-08-26
AU2004319276A1 (en) 2005-11-17
AU2004319276C1 (en) 2011-03-03
CR8698A (es) 2007-12-17
SI1734995T1 (sl) 2010-09-30
PL1734995T3 (pl) 2010-12-31
HK1094167A1 (en) 2007-03-23
DE602004028168D1 (de) 2010-08-26
EP1734995A1 (en) 2006-12-27
BRPI0418745A (pt) 2007-12-11
PT1734995E (pt) 2010-08-18
EP1734995A4 (en) 2007-04-25
CN1964738A (zh) 2007-05-16
KR20070012711A (ko) 2007-01-26
NZ550324A (en) 2009-12-24
IL178474A0 (en) 2007-02-11
ES2346886T3 (es) 2010-10-21
US7687063B2 (en) 2010-03-30
US20080019966A1 (en) 2008-01-24
EP1734995B1 (en) 2010-07-14
ATE473760T1 (de) 2010-07-15

Similar Documents

Publication Publication Date Title
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201000245A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
EA201100694A1 (ru) Антитело к cd38 человека и его применение
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
DK1684869T3 (da) Fremgangsmåde til terapi af B-celle-relaterede cancersygdomme
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
NO20064136L (no) Anti-epcam-immunglobuliner
CY1109817T1 (el) Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
TR200902344T1 (tr) Anti-epidermal büyüme faktörü reseptör antikorları ile terapinin etkisinin geliştirilmesi için terapötik bileşimler.